Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680140 · ClinicalTrials.gov registry record · Phase 4
Biomarker-Guided Antidepressant Selection
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT07680140 is a Phase 4 study that has not yet begun recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 27 participants.
The verdict
NCT07680140, a Phase 4 study, has not yet begun recruiting, sponsored by Weill Medical College of Cornell University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.
Interventions
- DEVICE TMS
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07680140
The ClinicalTrials.gov registry entry for NCT07680140 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TMS is the first listed.
NCT07680140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07680140 about?
NCT07680140 is a clinical study titled "Biomarker-Guided Antidepressant Selection". Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for peo...
What is the current status of trial NCT07680140?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07680140?
The interventions under investigation include: TMS (DEVICE), Ketamine (DRUG).
Who is sponsoring clinical trial NCT07680140?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.